<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ZOLEDRONIC ACID- zoledronic acid injection, solution, concentrate </strong><br>Akorn<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Zoledronic Acid Injection safely and effectively. See full prescribing information for Zoledronic Acid Injection. <br>Zoledronic Acid Injection, 4 mg/5 mL<br>Concentrate for Intravenous Infusion (For Single Use)<br>Initial U.S. Approval:  2001
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span> (<a href="#s26">5.10</a>)  09/2013
 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Zoledronic Acid Injection is a bisphosphonate indicated for the treatment of:
 </p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">Hypercalcemia of malignancy</span> (<a href="#s4">1.1</a>)
</li>
<li>Patients with <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> and patients with documented bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> from <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy (<a href="#s5">1.2</a>)
</li>
</ul>
<p class="Highlighta">Important limitation of use: The safety and efficacy of Zoledronic Acid Injection has not been established for use in <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span> or nontumor-related <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> (<a href="#s6">1.3</a>)
 </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">Hypercalcemia of malignancy</span> (<a href="#s8">2.1</a>)
 </p>
<ul class="Disc">
<li>4 mg as a single-use intravenous infusion over no less than 15 minutes.
</li>
<li>4 mg as retreatment after a minimum of 7 days.
</li>
</ul>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple myeloma</span> and bone <span class="product-label-link" type="condition" conceptid="4147162" conceptname="Secondary malignant neoplasm of respiratory and digestive systems">metastasis</span> from <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span> (<a href="#s9">2.2</a>)
 </p>
<ul class="Disc">
<li>4 mg as a single-use intravenous infusion over no less than 15 minutes every 3 to 4 weeks for patients with creatinine clearance of greater than 60 mL/min.
</li>
<li>Reduce the dose for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.
</li>
<li>Coadminister oral calcium supplements of 500 mg and a multiple vitamin containing 400 international units of Vitamin D daily.
</li>
</ul>
<p class="Highlighta">Administer through a separate vented infusion line and do not allow to come in contact with any calcium or divalent cation-containing solutions. (<a href="#s10">2.3</a>)
 </p>
</div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">4 mg/5 mL single-use vial of concentrate (<a href="#s13">3</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of Zoledronic Acid Injection (<a href="#s14">4</a>)
</li></ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Patients being treated with Zoledronic Acid Injection should not be treated with Reclast<span class="Sup">®</span> (<a href="#s17">5.1</a>)
</li>
<li>Adequately rehydrate patients with <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span> prior to administration of Zoledronic Acid Injection and monitor electrolytes during treatment. (<a href="#s18">5.2</a>)
</li>
<li>Renal toxicity may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Do not use doses greater than 4 mg. Treatment in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is not recommended. Monitor serum creatinine before each dose. (<a href="#s19">5.3</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Osteonecrosis</span> of the jaw has been reported. Preventive dental exams should be performed before starting Zoledronic Acid Injection. Avoid invasive dental procedures. (<a href="#s20">5.4</a>)
</li>
<li>Severe incapacitating bone, joint, and/or <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span> may occur. Discontinue Zoledronic Acid Injection if severe symptoms occur. (<a href="#s21">5.5</a>)
</li>
<li>Zoledronic Acid Injection can cause fetal harm.  Women of childbearing potential should be advised of the potential hazard to the fetus and to avoid becoming pregnant. (<a href="#s25">5.9</a>, <a href="#s50">8.1</a>)
</li>
<li>Atypical subtrochanteric and diaphyseal femoral <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> have been reported in patients receiving bisphosphonate therapy. These <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> may occur after minimal or no <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>. Evaluated patients with thigh or <span class="product-label-link" type="condition" conceptid="4010361" conceptname="Inguinal pain">groin pain</span> to rule out a femoral <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>. Consider drug discontinuation in patients suspected to have an atypical <span class="product-label-link" type="condition" conceptid="442560" conceptname="Fracture of femur">femur fracture</span>. (<a href="#s22">5.6</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span>: Correct before initiating Zoledronic Acid Injection. Adequately supplement patients with calcium and vitamin D. (<a href="#s26">5.10</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse events (greater than 25%) were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> (<a href="#s28">6.1</a>)
 </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Akorn 1 800-932-5676 or FDA 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Aminoglycosides: May have an additive effect to lower serum calcium for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span>. (<a href="#s45">7.1</a>)
</li>
<li>Loop diuretics: Concomitant use with Zoledronic Acid Injection may increase risk of <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>. (<a href="#s46">7.2</a>)
</li>
<li>Nephrotoxic drugs: Use with caution. (<a href="#s47">7.3</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Nursing Mothers: It is not known whether Zoledronic Acid Injection is excreted in human milk. (<a href="#s51">8.3</a>)
</li>
<li>Pediatric Use: Not indicated for use in pediatric patients. (<a href="#s52">8.4</a>)
</li>
<li>Geriatric Use: Special care to monitor renal function. (<a href="#s53">8.5</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 5/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1  INDICATIONS AND USAGE
</a></h1>
<h2><a href="#section-1.1" class="toc">1.1  <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">Hypercalcemia of Malignancy</span>
</a></h2>
<h2><a href="#section-1.2" class="toc">1.2  <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple Myeloma</span> and Bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">Metastases</span> of <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">Solid Tumors</span>
</a></h2>
<h2><a href="#section-1.3" class="toc">1.3  Important Limitation of Use
</a></h2>
<h1><a href="#section-2" class="toc">2  DOSAGE AND ADMINISTRATION
</a></h1>
<h2><a href="#section-2.1" class="toc">2.1  <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">Hypercalcemia of Malignancy</span>
</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple Myeloma</span> and Metastatic Bone Lesions of <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">Solid Tumors</span>
</a></h2>
<h2><a href="#section-2.3" class="toc">2.3  Preparation of Solution
</a></h2>
<h2><a href="#section-2.4" class="toc">2.4  Method of Administration
</a></h2>
<h1><a href="#section-3" class="toc">3  DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4  CONTRAINDICATIONS
</a></h1>
<h2><a href="#section-4.1" class="toc">4.1   <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to Zoledronic Acid or Any Components of Zoledronic Acid Injection
</a></h2>
<h1><a href="#section-5" class="toc">5  WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1  Drugs with Same Active Ingredient or in the Same Drug Class
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2  Hydration and Electrolyte Monitoring
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3  <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h2><a href="#section-5.4" class="toc">5.4  <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Osteonecrosis</span> of the Jaw
</a></h2>
<h2><a href="#section-5.5" class="toc">5.5  <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal Pain</span>
</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Atypical Subtrochanteric and Diaphyseal Femoral <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span>
</a></h2>
<h2><a href="#section-5.7" class="toc">5.7  Patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>
</a></h2>
<h2><a href="#section-5.8" class="toc">5.8  <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</a></h2>
<h2><a href="#section-5.9" class="toc">5.9  Use in Pregnancy
</a></h2>
<h2><a href="#section-5.10" class="toc">5.10  <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span>
</a></h2>
<h1><a href="#section-6" class="toc">6  ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1  Clinical Studies Experience
</a></h2>
<h2><a href="#section-6.2" class="toc">6.2  Postmarketing Experience
</a></h2>
<h1><a href="#section-7" class="toc">7  DRUG INTERACTIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">7.1  Aminoglycosides
</a></h2>
<h2><a href="#section-7.2" class="toc">7.2  Loop Diuretics
</a></h2>
<h2><a href="#section-7.3" class="toc">7.3  Nephrotoxic Drugs
</a></h2>
<h2><a href="#section-7.4" class="toc">7.4  Thalidomide
</a></h2>
<h1><a href="#section-8" class="toc">8  USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">8.1  Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">8.3  Nursing Mothers
</a></h2>
<h2><a href="#section-8.3" class="toc">8.4  Pediatric Use
</a></h2>
<h2><a href="#section-8.4" class="toc">8.5  Geriatric Use
</a></h2>
<h1><a href="#section-9" class="toc">10  OVERDOSAGE
</a></h1>
<h1><a href="#section-10" class="toc">11  DESCRIPTION
</a></h1>
<h1><a href="#section-11" class="toc">12  CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-11.1" class="toc">12.1  Mechanism of Action
</a></h2>
<h2><a href="#section-11.2" class="toc">12.2  Pharmacodynamics
</a></h2>
<h2><a href="#section-11.3" class="toc">12.3  Pharmacokinetics
</a></h2>
<h1><a href="#section-12" class="toc">13  NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-13" class="toc">14  CLINICAL STUDIES
</a></h1>
<h2><a href="#section-13.1" class="toc">14.1  <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">Hypercalcemia of Malignancy</span>
</a></h2>
<h2><a href="#section-13.2" class="toc">14.2   Clinical Trials in <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple Myeloma</span> and Bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">Metastases</span> of <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">Solid Tumors</span>
</a></h2>
<h1><a href="#section-14" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-15" class="toc">17  PATIENT COUNSELING INFORMATION
</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s3"></a><a name="section-1"></a><p></p>
<h1>1  INDICATIONS AND USAGE
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-1.1"></a><p></p>
<h2>1.1  <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">Hypercalcemia of Malignancy</span>
</h2>
<p class="First">Zoledronic Acid Injection is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span> defined as an albumin-corrected calcium (cCa) of greater than or equal to 12 mg/dL [3.0 mmol/L] using the formula: cCa in mg/dL=Ca in mg/dL + 0.8 (4.0 g/dL – patient albumin [g/dL]).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-1.2"></a><p></p>
<h2>1.2  <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple Myeloma</span> and Bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">Metastases</span> of <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">Solid Tumors</span>
</h2>
<p class="First">Zoledronic Acid Injection is indicated for the treatment of patients with <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> and patients with documented bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> from <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-1.3"></a><p></p>
<h2>1.3  Important Limitation of Use
</h2>
<p class="First">The safety and efficacy of zoledronic acid injection in the treatment of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> associated with <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span> or with other nontumor-related conditions have not been established.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s7"></a><a name="section-2"></a><p></p>
<h1>2  DOSAGE AND ADMINISTRATION
</h1>
<p class="First">Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-2.1"></a><p></p>
<h2>2.1  <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">Hypercalcemia of Malignancy</span>
</h2>
<p class="First">The maximum recommended dose of zoledronic acid injection in <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span> (albumin-corrected serum calcium greater than or equal to 12 mg/dL [3.0 mmol/L]) is 4 mg. The 4-mg dose must be given as a single-dose intravenous infusion over <span class="Bold">no less than 15 minutes</span>. Patients who receive zoledronic acid injection should have serum creatinine assessed prior to each treatment.
</p>
<p>Dose adjustments of zoledronic acid injection are not necessary in treating patients for <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span> presenting with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> prior to initiation of therapy (serum creatinine less than 400 μmol/L or less than 4.5 mg/dL).
</p>
<p>Patients should be adequately rehydrated prior to administration of zoledronic acid injection [see <span class="Italics">Warnings and Precautions (<a href="#s18">5.2</a>)</span>].
</p>
<p>Consideration should be given to the severity of, as well as the symptoms of, tumor-induced <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> when considering use of zoledronic acid injection. Vigorous saline hydration, an integral part of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but <span class="product-label-link" type="condition" conceptid="4266976" conceptname="Overhydration">overhydration</span>, especially in those patients who have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, must be avoided. Diuretic therapy should not be employed prior to correction of <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>.
</p>
<p>Retreatment with zoledronic acid injection 4 mg may be considered if serum calcium does not return to normal or remain normal after initial treatment. It is recommended that a minimum of 7 days elapse before retreatment, to allow for full response to the initial dose. Renal function must be carefully monitored in all patients receiving zoledronic acid injection and serum creatinine must be assessed prior to retreatment with zoledronic acid injection [see <span class="Italics">Warnings and Precautions (<a href="#s18">5.2</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-2.2"></a><p></p>
<h2>2.2 <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple Myeloma</span> and Metastatic Bone Lesions of <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">Solid Tumors</span>
</h2>
<p class="First">The recommended dose of zoledronic acid injection in patients with <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> and metastatic bone lesions from <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span> for patients with creatinine clearance (CrCl) greater than 60 mL/min is 4 mg infused over <span class="Bold">no less than 15 minutes</span> every 3 to 4 weeks. The optimal duration of therapy is not known.
</p>
<p>Upon treatment initiation, the recommended zoledronic acid injection doses for patients with reduced renal function (mild and moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>) are listed in <a href="#t1">Table 1</a>. These doses are calculated to achieve the same area under the curve (AUC) as that achieved in patients with creatinine clearance of 75 mL/ min. CrCl is calculated using the Cockcroft-Gault formula [see <span class="Italics">Warnings and Precautions (<a href="#s18">5.2</a>)</span>].
</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1: Reduced Doses for Patients with Baseline CrCl less than or equal to  60 mL/min
</span></caption>
<col align="left" width="50.000%">
<col align="left" width="50.000%">
<tfoot><tr class="First Last"><td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><p class="First Footnote">*Doses calculated assuming target AUC of 0.66(mg·hr/L) (CrCl = 75 mL/min)
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Baseline Creatinine Clearance  (mL/min)</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Zoledronic Acid Injection Recommended Dose*</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">greater than 60<br>50 to 60<br>40 to 49<br>30 to 39
</td>
<td class="Botrule Rrule" align="center" valign="top">4 mg<br>3.5 mg<br>3.3 mg<br>3 mg
</td>
</tr>
</tbody>
</table>
<p>During treatment, serum creatinine should be measured before each Zoledronic Acid Injection dose and treatment should be withheld for renal deterioration. In the clinical studies, renal deterioration was defined as follows:
</p>
<p>For patients with normal baseline creatinine, increase of 0.5 mg/dL
</p>
<p>For patients with abnormal baseline creatinine, increase of 1.0 mg/dL
</p>
<p>In the clinical studies, zoledronic acid injection treatment was resumed only when the creatinine returned to within 10% of the baseline value. Zoledronic Acid Injection should be reinitiated at the same dose as that prior to treatment interruption.
</p>
<p>Patients should also be administered an oral calcium supplement of 500 mg and a multiple vitamin containing 400 international units of Vitamin D daily.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-2.3"></a><p></p>
<h2>2.3  Preparation of Solution
</h2>
<p class="First">Zoledronic Acid Injection must not be mixed with calcium or other divalent cation-containing infusion solutions, such as Lactated Ringer's solution, and should be administered as a single intravenous solution in a line separate from all other drugs.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-2.3.1"></a><p></p>
<p class="First"><span class="Bold Underline">4 mg/5 mL Single-Use Vial</span></p>
<p>Vials of Zoledronic Acid Injection, concentrate for infusion contain overfill allowing for the withdrawal of 5 mL of concentrate (equivalent to 4 mg zoledronic acid). This concentrate should immediately be diluted in 100 mL of sterile 0.9% Sodium Chloride, USP, or 5% Dextrose Injection, USP following proper aseptic technique and administered to the patient by infusion. Do not store undiluted concentrate in a syringe, to avoid inadvertent injection.
</p>
<p>To prepare reduced doses for patients with baseline CrCl less than or equal to 60 mL/min, withdraw the specified volume of the Zoledronic Acid Injection concentrate from the vial for the dose required (see <a href="#t2">Table 2</a>).
</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2: Preparation of Reduced Doses – Zoledronic Acid Injection Concentrate
</span></caption>
<col align="left" width="66.950%">
<col align="left" width="33.050%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Remove and Use Zoledronic Acid Injection Volume (mL)</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Dose (mg)</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">4.4<br>4.1<br>3.8
</td>
<td class="Botrule Rrule" align="center" valign="top">3.5<br>3.3<br>3.0
</td>
</tr>
</tbody>
</table>
<p>The withdrawn concentrate must be diluted in 100 mL of sterile 0.9% Sodium Chloride, USP, or 5% Dextrose Injection, USP.
</p>
<p>If not used immediately after dilution with infusion media, for microbiological integrity, the solution should be refrigerated at 2°C to 8°C (36°F to 46°F). The refrigerated solution should then be equilibrated to room temperature prior to administration. The total time between dilution, storage in the refrigerator, and end of administration must not exceed 24 hours.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-2.4"></a><p></p>
<h2>2.4  Method of Administration
</h2>
<p class="First">Due to the risk of clinically significant deterioration in renal function, which may progress to <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, single doses of zoledronic acid injection should not exceed 4 mg and the duration of infusion should be no less than 15 minutes [<span class="Italics">see Warnings and Precautions (<a href="#s19">5.3</a>)</span>]. In the trials and in postmarketing experience, renal deterioration, progression to <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> and dialysis, have occurred in patients, including those treated with the approved dose of 4 mg infused over 15 minutes. There have been instances of this occurring after the initial zoledronic acid injection dose.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s13"></a><a name="section-3"></a><p></p>
<h1>3  DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">4 mg/5 mL single-use vial of concentrate
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s14"></a><a name="section-4"></a><p></p>
<h1>4  CONTRAINDICATIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-4.1"></a><p></p>
<h2>4.1   <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to Zoledronic Acid or Any Components of Zoledronic Acid Injection
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> including rare cases of <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and very rare cases of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>/<span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> have been reported [see <span class="Italics">Adverse Reactions (<a href="#s37">6.2</a>)</span>].
</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s16"></a><a name="section-5"></a><p></p>
<h1>5  WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-5.1"></a><p></p>
<h2>5.1  Drugs with Same Active Ingredient or in the Same Drug Class
</h2>
<p class="First">Zoledronic Acid Injection contains the same active ingredient as found in Reclast<span class="Sup">®</span> (zoledronic acid). Patients being treated with Zoledronic Acid Injection should not be treated with Reclast or other bisphosphonates.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-5.2"></a><p></p>
<h2>5.2  Hydration and Electrolyte Monitoring
</h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span> must be adequately rehydrated prior to administration of zoledronic acid injection. Loop diuretics should not be used until the patient is adequately rehydrated and should be used with caution in combination with zoledronic acid injection in order to avoid <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>. Zoledronic Acid Injection should be used with caution with other nephrotoxic drugs. Standard <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>-related metabolic parameters, such as serum levels of calcium, phosphate, and magnesium, as well as serum creatinine, should be carefully monitored following initiation of therapy with zoledronic acid injection. If <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>, or <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> occur, short-term supplemental therapy may be necessary.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-5.3"></a><p></p>
<h2>5.3  <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">Zoledronic Acid Injection is excreted intact primarily via the kidney, and the risk of adverse reactions, in particular renal adverse reactions, may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Safety and pharmacokinetic data are limited in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and the risk of renal deterioration is increased [see <span class="Italics">Adverse Reactions (<a href="#s28">6.1</a>)</span>]. Preexisting <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> and multiple cycles of zoledronic acid injection and other bisphosphonates are risk factors for subsequent renal deterioration with zoledronic acid injection. Factors predisposing to renal deterioration, such as <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> or the use of other nephrotoxic drugs, should be identified and managed, if possible.
</p>
<p>Zoledronic Acid Injection treatment in patients with <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span> with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> should be considered only after evaluating the risks and benefits of treatment. In the clinical studies, patients with serum creatinine greater than 400 μmol/L or greater than 4.5 mg/dL were excluded.
</p>
<p>Zoledronic Acid Injection treatment is not recommended in patients with bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. In the clinical studies, patients with serum creatinine greater than 265 μmol/L or greater than 3.0 mg/dL were excluded and there were only 8 of 564 patients treated with zoledronic acid injection 4 mg by 15-minute infusion with a baseline creatinine greater than 2 mg/dL. Limited pharmacokinetic data exists in patients with creatinine clearance less than 30 mL/ min [see <span class="Italics">Clinical Pharmacology (<a href="#s59">12.3</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-5.4"></a><p></p>
<h2>5.4  <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Osteonecrosis</span> of the Jaw
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Osteonecrosis</span> of the jaw (ONJ) has been reported predominantly in cancer patients treated with intravenous bisphosphonates, including zoledronic acid injection. Many of these patients were also receiving chemotherapy and corticosteroids which may be risk factors for ONJ. Postmarketing experience and the literature suggest a greater frequency of reports of ONJ based on tumor type (advanced breast cancer, <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span>), and dental status (dental extraction, <span class="product-label-link" type="condition" conceptid="134398" conceptname="Periodontal disease">periodontal disease</span>, local <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> including poorly fitting dentures). Many reports of ONJ involved patients with signs of local <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> including <span class="product-label-link" type="condition" conceptid="141663" conceptname="Osteomyelitis">osteomyelitis</span>.
</p>
<p>Cancer patients should maintain good oral hygiene and should have a dental examination with preventive dentistry prior to treatment with bisphosphonates.
</p>
<p>While on treatment, these patients should avoid invasive dental procedures if possible. For patients who develop ONJ while on bisphosphonate therapy, dental surgery may exacerbate the condition. For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of ONJ. Clinical judgment of the treating physician should guide the management plan of each patient based on individual benefit/risk assessment [see <span class="Italics">Adverse Reactions (<a href="#s37">6.2</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-5.5"></a><p></p>
<h2>5.5  <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal Pain</span>
</h2>
<p class="First">In postmarketing experience, severe and occasionally incapacitating bone, joint, and/or <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span> has been reported in patients taking bisphosphonates, including zoledronic acid injection. The time to onset of symptoms varied from one day to several months after starting the drug. Discontinue use if severe symptoms develop. Most patients had relief of symptoms after stopping. A subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate [see <span class="Italics">Adverse Reactions (<a href="#s37">6.2</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Atypical Subtrochanteric and Diaphyseal Femoral <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span>
</h2>
<p class="First">Atypical subtrochanteric and diaphyseal femoral <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> have been reported in patients receiving bisphosphonate therapy, including zoledronic acid injection. These <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> can occur anywhere in the femoral shaft from just below the lesser trochanter to just above the supracondylar flare and are transverse or short oblique in orientation without evidence of comminution. These <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> occur after minimal or no <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>. Patients may experience thigh or <span class="product-label-link" type="condition" conceptid="4010361" conceptname="Inguinal pain">groin pain</span> weeks to months before presenting with a completed femoral <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>. <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span> are often bilateral; therefore the contralateral femur should be examined in bisphosphonate-treated patients who have sustained a femoral shaft <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>. Poor healing of these <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> has also been reported. A number of case reports noted that patients were also receiving treatment with glucocorticoids (such as prednisone or dexamethasone) at the time of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>. Causality with bisphosphonate therapy has not been established.
</p>
<p>Any patient with a history of bisphosphonate exposure who presents with thigh or <span class="product-label-link" type="condition" conceptid="4010361" conceptname="Inguinal pain">groin pain</span> in the absence of <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> should be suspected of having an atypical <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> and should be evaluated. Discontinuation of zoledronic acid injection therapy in patients suspected to have an atypical <span class="product-label-link" type="condition" conceptid="442560" conceptname="Fracture of femur">femur fracture</span> should be considered pending evaluation of the patient, based on an individual benefit risk assessment. It is unknown whether the risk of atypical <span class="product-label-link" type="condition" conceptid="442560" conceptname="Fracture of femur">femur fracture</span> continues after stopping therapy.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-5.7"></a><p></p>
<h2>5.7  Patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>
</h2>
<p class="First">While not observed in clinical trials with zoledronic acid injection, there have been reports of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span> in aspirin sensitive patients receiving bisphosphonates.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-5.8"></a><p></p>
<h2>5.8  <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</h2>
<p class="First">Only limited clinical data are available for use of zoledronic acid injection to treat <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span> in patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>, and these data are not adequate to provide guidance on dosage selection or how to safely use zoledronic acid injection in these patients.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-5.9"></a><p></p>
<h2>5.9  Use in Pregnancy
</h2>
<p class="First">Bisphosphonates, such as zoledronic acid injection, are incorporated into the bone matrix, from where they are gradually released over periods of weeks to years. There may be a risk of fetal harm (e.g., skeletal and other abnormalities) if a woman becomes pregnant after completing a course of bisphosphonate therapy.
</p>
<p>Zoledronic Acid Injection may cause fetal harm when administered to a pregnant woman. In reproductive studies in pregnant rats, subcutaneous doses equivalent to 2.4 or 4.8 times the human systemic exposure resulted in pre- and postimplantation losses, decreases in viable fetuses and fetal skeletal, visceral, and external malformations. There are no adequate and well controlled studies in pregnant women.  If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see <span class="Italics">Use In Specific Populations (<a href="#s50">8.1</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-5.10"></a><p></p>
<h2>5.10  <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span> has been reported in patients treated with zoledronic acid injection. <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac arrhythmias</span> and neurologic adverse events (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span>, and <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>) have been reported secondary to cases of severe <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>. In some instances, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> may be life-threatening. <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span> must be corrected before initiating zoledronic acid injection. Adequately supplement patients with calcium and vitamin D.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s27"></a><a name="section-6"></a><p></p>
<h1>6  ADVERSE REACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-6.1"></a><p></p>
<h2>6.1  Clinical Studies Experience
</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold Underline"><span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">Hypercalcemia of Malignancy</span></span></p>
<p>The safety of zoledronic acid injection was studied in 185 patients with <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span> (HCM) who received either zoledronic acid injection 4 mg given as a 5-minute intravenous infusion (n=86) or pamidronate 90 mg given as a 2-hour intravenous infusion (n=103). The population was aged 33 to 84 years, 60% male and 81% Caucasian, with breast, lung, head and neck, and <span class="product-label-link" type="condition" conceptid="196653" conceptname="Malignant tumor of kidney">renal cancer</span> as the most common forms of malignancy. NOTE: pamidronate 90 mg was given as a 2-hour intravenous infusion. The relative safety of pamidronate 90 mg given as a 2-hour intravenous infusion compared to the same dose given as a 24-hour intravenous infusion has not been adequately studied in controlled clinical trials.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Bold Underline">Renal Toxicity</span></p>
<p>Administration of zoledronic acid injection 4 mg given as a 5-minute intravenous infusion has been shown to result in an increased risk of renal toxicity, as measured by increases in serum creatinine, which can progress to <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. The incidence of renal toxicity and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> has been shown to be reduced when zoledronic acid injection 4 mg is given as a 15-minute intravenous infusion. Zoledronic Acid Injection should be administered by intravenous infusion over no less than 15 minutes [<span class="Italics">see Warnings and Precautions (<a href="#s19">5.3</a>)</span> and <span class="Italics">Dosage and Administration (<a href="#s12">2.4</a>)</span>].
</p>
<p>The most frequently observed adverse events were <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> (see <a href="#t3">Table 3</a>).
</p>
<p><a href="#t3">Table 3</a> provides adverse events that were reported by 10% or more of the 189 patients treated with Zoledronic Acid Injection 4 mg or Pamidronate 90 mg from the two HCM trials. Adverse events are listed regardless of presumed causality to study drug.
</p>
<a name="t3"></a><table width="100%">
<caption><span>Table 3. Percentage of Patients with Adverse Events ≥10% Reported in <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">Hypercalcemia of Malignancy</span> Clinical Trials by Body System
</span></caption>
<col align="left" width="30.320%">
<col align="left" width="18.200%">
<col align="left" width="17.120%">
<col align="left" width="15.140%">
<col align="left" width="19.220%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Zoledronic Acid Injection 4 mg  n(%)</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Pamidronate 90 mg  n(%)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">Patients Studied</span><br>Total No. of Patients Studied Total No. of Patients with any AE
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>86<br>81
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(100)<br>(94)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>103<br>95
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(100)<br>(92)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">Body as a Whole</span><br><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span><br>Progression of Cancer
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>38<br>14
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(44)<br>(16)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>34<br>21
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(33)<br>(20)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">Cardiovascular
</span><br><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>9
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(11)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>2
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(2)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">Digestive
</span><br><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span><br><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span><br><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span><br><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span><br><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>25<br>23<br>15<br>14<br>12<br>8
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(29)<br>(27)<br>(17)<br>(16)<br>(14)<br>(9)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>28<br>13<br>17<br>13<br>17<br>14
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(27)<br>(13)<br>(17)<br>(13)<br>(17)<br>(14)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">Hemic and Lymphatic</span><br><span class="Bold">System</span><br> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br><br>19
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br><br>(22)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br><br>18
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br><br>(18)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span><br> <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Moniliasis</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<br>10
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<br>(12)
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<br>4
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<br>(4)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">Laboratory Abnormalities</span><br><span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">Hypophosphatemia</span><br><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span><br><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>11<br>10<br>9
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(13)<br>(12)<br>(11)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>2<br>16<br>5
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(2)<br>(16)<br>(5)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">Musculoskeletal</span><br> <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">Skeletal Pain</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>10
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(12)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>10
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(10)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">Nervous</span><br><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span><br><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span><br><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span><br><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">13<br>12<br>11<br>11
</td>
<td class="Botrule Rrule" align="center" valign="bottom">(15)<br>(14)<br>(13)<br>(13)
</td>
<td class="Botrule Rrule" align="center" valign="bottom">10<br>8<br>13<br>8
</td>
<td class="Botrule Rrule" align="center" valign="bottom">(10)<br>(8)<br>(13)<br>(8)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">Respiratory</span><br> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span><br><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<br>19<br>10
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<br>(22)<br>(12)
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<br>20<br>12
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<br>(19)<br>(12)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">Urogenital</span><br><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>12
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(14)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>15
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(15)
</td>
</tr>
</tbody>
</table>
<p>The following adverse events from the two controlled multicenter HCM trials (n=189) were reported by a greater percentage of patients treated with zoledronic acid injection 4 mg than with pamidronate 90 mg and occurred with a frequency of greater than or equal to 5% but less than 10%. Adverse events are listed regardless of presumed causality to study drug: <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">leg edema</span>, <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, nonspecific <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgias</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.
</p>
<p>Rare cases of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> have been reported following treatment with zoledronic acid injection.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Bold Underline">Acute Phase Reaction</span></p>
<p>Within three days after zoledronic acid injection administration, an acute phase reaction has been reported in patients, with symptoms including <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span> and/or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgias</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, and <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like illness. These symptoms usually resolve within a few days. <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span> has been the most commonly associated symptom, occurring in 44% of patients.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-6.1.4"></a><p></p>
<p class="First"><span class="Bold Underline">Mineral and Electrolyte Abnormalities</span></p>
<p>Electrolyte abnormalities, most commonly <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span> and <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, can occur with bisphosphonate use.
</p>
<p>Grade 3 and Grade 4 laboratory abnormalities for serum creatinine, serum calcium, serum phosphorus, and serum magnesium observed in two clinical trials of zoledronic acid injection in patients with HCM are shown in <a href="#t4">Table 4</a> and <a href="#t5">Table 5</a>.
</p>
<a name="t4"></a><table width="100%">
<caption><span>Table 4: Grade 3 Laboratory Abnormalities for Serum Creatinine, Serum Calcium, Serum Phosphorus, and Serum Magnesium in Two Clinical Trials in Patients with HCM
</span></caption>
<col align="left" width="44.429%">
<col align="left" width="13.123%">
<col align="left" width="13.923%">
<col align="left" width="13.843%">
<col align="left" width="14.683%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="middle">Laboratory Parameter
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top">Grade 3
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">Zoledronic Acid Injection 4 mg
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">Pamidronate 90 mg
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="bottom">Serum Creatinine<span class="Sup">1</span><br><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span><span class="Sup">2</span><br><span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">Hypophosphatemia</span><span class="Sup">3</span><br><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span><span class="Sup">4</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">n/N</span><br>2/86<br>1/86<br>36/70<br>0/71
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">(%)</span><br>(2%)<br>(1%)<br>(51%)<br>–
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">n/N</span><br>3/100<br>2/100<br>27/81<br>0/84
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">(%)</span><br>(3%)<br>(2%)<br>(33%)<br>–
</td>
</tr>
</tbody>
</table>
<a name="t5"></a><table width="100%">
<caption><span>Table 5: Grade 4 Laboratory Abnormalities for Serum Creatinine, Serum Calcium, Serum Phosphorus, and Serum Magnesium in Two Clinical Trials in Patients with HCM
</span></caption>
<col align="left" width="46.049%">
<col align="left" width="12.082%">
<col align="left" width="12.402%">
<col align="left" width="15.643%">
<col align="left" width="13.823%">
<tfoot>
<tr class="First"><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">1</span>  Grade 3 (greater than 3x Upper Limit of Normal); Grade 4 (greater than 6x Upper Limit of Normal)
</p></td></tr>
<tr><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">2</span> Grade 3 (less than 7 mg/dL); Grade 4 (less than 6 mg/dL)
</p></td></tr>
<tr><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">3</span> Grade 3 (less than 2 mg/dL); Grade 4 (less than 1 mg/dL)
</p></td></tr>
<tr class="Last"><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">4</span> Grade 3 (less than 0.8 mEq/L); Grade 4 (less than 0.5 mEq/L)
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="middle">Laboratory Parameter
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top">Grade 4
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">Zoledronic Acid Injection 4 mg
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">Pamidronate 90 mg
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="bottom">Serum Creatinine<span class="Sup">1</span><br><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span><span class="Sup">2</span><br><span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">Hypophosphatemia</span><span class="Sup">3</span><br><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span><span class="Sup">4</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">n/N</span><br>0/86<br>0/86<br>1/70<br>0/71
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">(%)</span><br>–<br>–<br>(1%)<br>–
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">n/N</span><br>1/100<br>0/100<br>4/81<br>1/84
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">(%)</span><br>(1%)<br>–<br>(5%)<br>(1%)
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-6.1.5"></a><p></p>
<p class="First"><span class="Bold Underline"><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection Site Reactions</span></span></p>
<p>Local reactions at the infusion site, such as <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, were observed infrequently. In most cases, no specific treatment is required and the symptoms subside after 24 to 48 hours.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s34"></a><a name="section-6.1.6"></a><p></p>
<p class="First"><span class="Bold Underline">Ocular Adverse Events</span></p>
<p>Ocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> such as <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> and <span class="product-label-link" type="condition" conceptid="434944" conceptname="Scleritis">scleritis</span> can occur with bisphosphonate use, including zoledronic acid injection. No cases of <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>, <span class="product-label-link" type="condition" conceptid="434944" conceptname="Scleritis">scleritis</span> or <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> were reported during these clinical trials. However, cases have been seen in postmarketing use [see <span class="Italics">Adverse Reactions (<a href="#s37">6.2</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-6.1.7"></a><p></p>
<p class="First"><span class="Bold Underline"><span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple Myeloma</span> and Bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">Metastases</span> of <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">Solid Tumors</span></span></p>
<p>The safety analysis includes patients treated in the core and extension phases of the trials. The analysis includes the 2,042 patients treated with zoledronic acid injection 4 mg, pamidronate 90 mg, or placebo in the three controlled multicenter bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> trials, including 969 patients completing the efficacy phase of the trial, and 619 patients that continued in the safety extension phase. Only 347 patients completed the extension phases and were followed for 2 years (or 21 months for the other <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumor</span> patients). The median duration of exposure for safety analysis for zoledronic acid injection 4 mg (core plus extension phases) was 12.8 months for breast cancer and <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span>, 10.8 months for prostate cancer, and 4.0 months for other <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>.
</p>
<p><a href="#t6">Table 6</a> describes adverse events that were reported by 10% or more of patients. Adverse events are listed regardless of presumed causality to study drug.
</p>
<a name="t6"></a><table width="100%">
<caption><span>Table 6: Percentage of Patients with Adverse Events ≥10% Reported in Three Bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">Metastases</span> Clinical Trials by Body System
</span></caption>
<col align="left" width="13.731%">
<col align="left" width="13.945%">
<col align="left" width="14.516%">
<col align="left" width="14.331%">
<col align="left" width="19.060%">
<col align="left" width="10.473%">
<col align="left" width="13.945%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top">
<span class="Bold">Zoledronic</span><br><span class="Bold">Acid Injection</span><br><span class="Bold">4 mg  n (%)</span>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top">
<span class="Bold">Pamidronate</span><br><span class="Bold">90 mg n (%)</span>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Placebo n (%)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">Patients Studied</span><br>Total No. of Patients Total No. of Patients with any AE
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>1031<br>1015
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(100)<br>(98)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>556<br>548
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(100)<br>(99)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>455<br>445
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(100)<br>(98)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">Blood and Lymphatic</span><br><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span><br>Neotropenia<br><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>344<br>124<br>102
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(33)<br>(12)<br>(10)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>175<br>83<br>53
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(32)<br>(15)<br>(10)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>128<br>35<br>20
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(28)<br>(8)<br>(4)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">Gastrointestinal</span><br><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span><br><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span><br><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span><br><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span><br><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span><br><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span><br><span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">Sore Throat</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>476<br>333<br>320<br>249<br>143<br>105<br>86<br>82
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(46)<br>(32)<br>(31)<br>(24)<br>(14)<br>(10)<br>(8)<br>(8)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>266<br>183<br>162<br>162<br>81<br>74<br>65<br>61
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(48)<br>(33)<br>(29)<br>(29)<br>(15)<br>(13)<br>(12)<br>(11)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>171<br>122<br>174<br>83<br>48<br>31<br>14<br>17
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(38)<br>(27)<br>(38)<br>(18)<br>(11)<br>(7)<br>(3)<br>(4)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">General Disorders and</span><br><span class="Bold">Administration Site</span><br><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span><br><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span><br><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span><br><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema Lower Limb</span><br><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Rigors</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">398<br>328<br>252<br>215<br>112
</td>
<td class="Botrule Rrule" align="center" valign="bottom">(39)<br>(32)<br>(24)<br>(21)<br>(11)
</td>
<td class="Botrule Rrule" align="center" valign="bottom">240<br>172<br>108<br>126<br>62
</td>
<td class="Botrule Rrule" align="center" valign="bottom">(43)<br>(31)<br>(19)<br>(23)<br>(11)
</td>
<td class="Botrule Rrule" align="center" valign="bottom">130<br>89<br>114<br>84<br>28
</td>
<td class="Botrule Rrule" align="center" valign="bottom">(29)<br>(20)<br>(25)<br>(19)<br>(6)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span><br><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span><br>Upper Respiratory Tract<br><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>124<br>101
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(12)<br>(10)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>50<br>82
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(9)<br>(15)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>41<br>30
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(9)<br>(7)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">Metabolism</span><br><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span><br><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Decreased</span><br><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span><br><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Appetite Decreased</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>231<br>164<br>145<br>130
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(22)<br>(16)<br>(14)<br>(13)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>81<br>50<br>60<br>48
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(15)<br>(9)<br>(11)<br>(9)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>105<br>61<br>59<br>45
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(23)<br>(13)<br>(13)<br>(10)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">Musculoskeletal</span><br><span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">Bone Pain</span><br><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span><br><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span><br><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span><br><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in Limb</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>569<br>239<br>216<br>156<br>143
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(55)<br>(23)<br>(21)<br>(15)<br>(14)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>316<br>143<br>131<br>106<br>84
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(57)<br>(26)<br>(24)<br>(19)<br>(15)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>284<br>74<br>73<br>40<br>52
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(62)<br>(16)<br>(16)<br>(9)<br>(11)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">Neoplasms</span><br>Malignant Neoplasm<br>Aggravated
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>205
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(20)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>97
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(17)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>89
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(20)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">Nervous</span><br><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span><br>Dizziness (excluding <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>)<br><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span><br><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span><br><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypoesthesia</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">191<br>180<br>166<br>149<br>127
</td>
<td class="Botrule Rrule" align="center" valign="bottom">(19)<br>(18)<br>(16)<br>(15)<br>(12)
</td>
<td class="Botrule Rrule" align="center" valign="bottom">149<br>91<br>111<br>85<br>65
</td>
<td class="Botrule Rrule" align="center" valign="bottom">(27)<br>(16)<br>(20)<br>(15)<br>(12)
</td>
<td class="Botrule Rrule" align="center" valign="bottom">50<br>58<br>73<br>35<br>43
</td>
<td class="Botrule Rrule" align="center" valign="bottom">(11)<br>(13)<br>(16)<br>(8)<br>(10)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">Psychiatric</span><br><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span><br><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span><br><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>146<br>112<br>74
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(14)<br>(11)<br>(7)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>95<br>73<br>39
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(17)<br>(13)<br>(7)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>49<br>37<br>47
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>(11)<br>(8)<br>(10)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">Respiratory</span><br><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span><br><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<br>282<br>224
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<br>(27)<br>(22)
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<br>155<br>129
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<br>(28)<br>(23)
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<br>107<br>65
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<br>(24)<br>(14)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">Skin</span><br><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span><br><span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Dermatitis</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">125<br>114
</td>
<td class="Botrule Rrule" align="center" valign="bottom">(12)<br>(11)
</td>
<td class="Botrule Rrule" align="center" valign="bottom">80<br>74
</td>
<td class="Botrule Rrule" align="center" valign="bottom">(14)<br>(13)
</td>
<td class="Botrule Rrule" align="center" valign="bottom">36<br>38
</td>
<td class="Botrule Rrule" align="center" valign="bottom">(8)<br>(8)
</td>
</tr>
</tbody>
</table>
<p>Grade 3 and Grade 4 laboratory abnormalities for serum creatinine, serum calcium, serum phosphorus, and serum magnesium observed in three clinical trials of Zoledronic Acid Injection in patients with bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> are shown in <a href="#t7">Table 7</a> and <a href="#t8">Table 8</a>.
</p>
<a name="t7"></a><table width="100%">
<caption><span>Table 7: Grade 3 Laboratory Abnormalities for Serum Creatinine, Serum Calcium, Serum Phosphorus, and Serum Magnesium in Three Clinical Trials in Patients with Bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">Metastases</span>
</span></caption>
<col align="left" width="39.649%">
<col align="left" width="11.730%">
<col align="left" width="9.358%">
<col align="left" width="10.273%">
<col align="left" width="9.358%">
<col align="left" width="10.273%">
<col align="left" width="9.358%">
<tfoot>
<tr class="First"><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">1</span> Grade 3 (greater than 3x Upper Limit of Normal); Grade 4 (greater than 6x Upper Limit of Normal)
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote">* Serum creatinine data for all patients randomized after the 15-minute infusion amendment
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Bold"><span class="Sup">2</span></span> Grade 3 (less than 7 mg/dL); Grade 4 (less than 6 mg/dL)
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">3</span> Grade 3 (less than 2 mg/dL); Grade 4 (less than 1 mg/dL)
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">4</span> Grade 3 (less than 3 mEq/L); Grade 4 (less than 8 mEq/L)
</p></td></tr>
<tr class="Last"><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">5</span> Grade 3 (less than 0.9 mEq/L); Grade 4 (less than 0.7 mEq/L)
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="middle"><span class="Bold">Laboratory Parameter</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"></td>
<td class="Botrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Grade 3</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">
<span class="Bold">Zoledronic Acid</span><br><span class="Bold">Injection</span><br><span class="Bold">4 mg</span>
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">Pamidronate 90 mg</span></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"><span class="Bold">Placebo</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="bottom">Serum Creatinine<span class="Sup">1*</span><br><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span><span class="Sup">2</span><br><span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">Hypophosphatemia</span><span class="Sup">3</span><br><span class="product-label-link" type="condition" conceptid="4284559" conceptname="Hypermagnesemia">Hypermagnesemia</span><span class="Sup">4</span><br><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span><span class="Sup">5</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">n/N</span><br>7/529<br>6/973<br>115/973<br>19/971<br>1/971
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">(%)</span><br>(1%)<br>(&lt;1%)<br>(12%)<br>(2%)<br>(&lt;1%)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">n/N</span><br>4/268<br>4/536<br>38/537<br>2/535<br>0/535
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">(%)</span><br>(2%)<br>(&lt;1%)<br>(7%)<br>(&lt;1%)<br>–
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">n/N</span><br>4/241<br>0/415<br>14/415<br>8/415<br>1/415
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">(%)</span><br>(2%)<br>–<br>(3%)<br>(2%)<br>(&lt;1%)
</td>
</tr>
</tbody>
</table>
<a name="t8"></a><table width="100%">
<caption><span>Table 8: Grade 4 Laboratory Abnormalities for Serum Creatinine, Serum Calcium, Serum Phosphorus, and Serum Magnesium in Three Clinical Trials in Patients with Bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">Metastases</span>
</span></caption>
<col align="left" width="31.867%">
<col align="left" width="10.656%">
<col align="left" width="11.284%">
<col align="left" width="11.256%">
<col align="left" width="11.927%">
<col align="left" width="10.656%">
<col align="left" width="12.355%">
<tfoot>
<tr class="First"><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">1</span> Grade 3 (greater than 3x Upper Limit of Normal); Grade 4 (greater than 6x Upper Limit of Normal)
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote">* Serum creatinine data for all patients randomized after the 15-minute infusion amendment
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote">Grade 3 (less than 7 mg/dL); Grade 4 (less than 6 mg/dL)
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote">Grade 3 (less than 2 mg/dL); Grade 4 (less than 1 mg/dL)
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote">Grade 3 (less than 3 mEq/L); Grade 4 (less than 8 mEq/L)
</p></td></tr>
<tr class="Last"><td align="left" colspan="7" valign="top"><p class="First Footnote">Grade 3 (less than 0.9 mEq/L); Grade 4 (less than 0.7 mEq/L)
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="middle"><span class="Bold">Laboratory Parameter</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"></td>
<td class="Botrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Grade 4</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" colspan="2" valign="top">
<span class="Bold">Zoledronic Acid</span><br><span class="Bold">Injection</span><br><span class="Bold">4 mg</span>
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">Pamidronate 90 mg</span></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"><span class="Bold">Placebo</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="bottom">Serum Creatinine<span class="Sup">1*</span><br><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span><span class="Sup">2</span><br> <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">Hypophosphatemia</span><span class="Sup">3</span><br><span class="product-label-link" type="condition" conceptid="4284559" conceptname="Hypermagnesemia">Hypermagnesemia</span><span class="Sup">4</span><br> <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span><span class="Sup">5</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">n/N</span><br>2/529<br>7/973<br>5/973<br>0/971<br>2/971
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">(%)</span><br>(&lt;1%)<br>(&lt;1%)<br>(&lt;1%)<br>–<br>(&lt;1%)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">n/N</span><br>1/268<br>3/536<br>0/537<br>0/535<br>1/535
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">(%)</span><br>(&lt;1%)<br>(&lt;1%)<br>–<br>–<br>(&lt;1%)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">n/N</span><br>0/241<br>2/415<br>1/415<br>2/415<br>0/415
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">(%)</span><br>–<br>(&lt;1%)<br>(&lt;1%))<br>(&lt;1%)<br>–
</td>
</tr>
</tbody>
</table>
<p>Among the less frequently occurring adverse events (less than 15% of patients), <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like illness, and <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> showed a trend for more events with bisphosphonate administration (Zoledronic Acid Injection 4 mg and pamidronate groups) compared to the placebo group.
</p>
<p>Less common adverse events reported more often with zoledronic acid injection 4 mg than pamidronate included decreased weight, which was reported in 16% of patients in the zoledronic acid injection 4 mg group compared with 9% in the pamidronate group. <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span> was reported in slightly more patients in the zoledronic acid injection 4 mg group (13%) compared with the pamidronate (9%) and placebo (10%) groups, but the clinical significance of these small differences is not clear.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s36"></a><a name="section-6.1.8"></a><p></p>
<p class="First"><span class="Bold Underline">Renal Toxicity</span></p>
<p>In the bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> trials, renal deterioration was defined as an increase of 0.5 mg/dL for patients with normal baseline creatinine (less than 1.4 mg/dL) or an increase of 1.0 mg/dL for patients with an abnormal baseline creatinine (greater than or equal to 1.4 mg/dL). The following are data on the incidence of renal deterioration in patients receiving Zoledronic Acid Injection 4 mg over 15 minutes in these trials (see <a href="#t9">Table 9</a>).
</p>
<a name="t9"></a><table width="100%">
<caption><span>Table 9: Percentage of Patients with Treatment Emergent Renal Function Deterioration by Baseline Serum Creatinine*
</span></caption>
<col align="left" width="30.480%">
<col align="left" width="18.400%">
<col align="left" width="16.360%">
<col align="left" width="18.400%">
<col align="left" width="16.360%">
<tfoot><tr class="First Last"><td align="left" colspan="5" valign="top"><p class="First Footnote">* Table includes only patients who were randomized to the trial after a protocol amendment that lengthened the infusion duration of Zoledronic Acid Injection to 15 minutes.
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="left" colspan="5" valign="top"><span class="Bold">Patient Population/Baseline Creatinine</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple Myeloma</span> and Breast Cancer</span></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">Zoledronic Acid Injection 4 mg</span></td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top"><span class="Bold">Pamidronate 90 mg</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom">Normal<br>Abnormal<br>Total
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">n/N</span><br>27/246<br>2/26<br>29/272
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">(%)</span><br>(11%)<br>(8%)<br>(11%)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">n/N</span><br>23/246<br>2/22<br>25/268
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">(%)</span><br>(9%)<br>(9%)<br>(9%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">Solid Tumors</span></span></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">Zoledronic Acid Injection 4 mg</span></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">Placebo</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="bottom">Normal<br>Abnormal<br>Total
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">n/N</span><br>17/154<br>1/11<br>18/165
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">(%)</span><br>(11%)<br>(9%)<br>(11%)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">n/N</span><br>10/143<br>1/20<br>11/163
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">(%)</span><br>(7%)<br>(5%)<br>(7%)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Prostate Cancer</span></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">Zoledronic Acid Injection 4 mg</span></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">Placebo</span></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="bottom">Normal<br>Abnormal<br>Total
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">n/N</span><br>12/82<br>4/10<br>16/92
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">(%)</span><br>(15%)<br>(40%)<br>(17%)
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">n/N</span><br>8/68<br>2/10<br>10/78
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">(%)</span><br>(12%)<br>(20%)<br>(13%)
</td>
</tr>
</tbody>
</table>
<p>The risk of deterioration in renal function appeared to be related to time on study, whether patients were receiving zoledronic acid injection (4 mg over 15 minutes), placebo, or pamidronate.
</p>
<p>In the trials and in postmarketing experience, renal deterioration, progression to <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> and dialysis have occurred in patients with normal and abnormal baseline renal function, including patients treated with 4 mg infused over a 15-minute period. There have been instances of this occurring after the initial zoledronic acid injection dose.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-6.2"></a><p></p>
<h2>6.2  Postmarketing Experience
</h2>
<p class="First">The following adverse reactions have been reported during postapproval use of zoledronic acid injection. Because these reports are from a population of uncertain size and are subject to confounding factors, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s38"></a><a name="section-6.2.1"></a><p></p>
<p class="First"><span class="Bold Underline"><span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Osteonecrosis</span> of the Jaw</span></p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">osteonecrosis</span> (primarily involving the jaws) have been reported predominantly in cancer patients treated with intravenous bisphosphonates including zoledronic acid injection. Many of these patients were also receiving chemotherapy and corticosteroids which may be a risk factor for ONJ. Data suggest a greater frequency of reports of ONJ in certain cancers, such as advanced breast cancer and <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span>. The majority of the reported cases are in cancer patients following invasive dental procedures, such as tooth extraction. It is therefore prudent to avoid invasive dental procedures as recovery may be prolonged [see <span class="Italics">Warnings and Precautions (<a href="#s20">5.4</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s39"></a><a name="section-6.2.2"></a><p></p>
<p class="First"><span class="Bold Underline">Acute Phase Reaction</span></p>
<p>Within three days after zoledronic acid injection administration, an acute phase reaction has been reported, with symptoms including <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span> and/or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgias</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like illness and <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> with subsequent <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>; these symptoms usually resolve within three days of onset, but resolution could take up to 7 to 14 days. However, some of these symptoms have been reported to persist for a longer duration.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-6.2.3"></a><p></p>
<p class="First"><span class="Bold Underline"><span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal Pain</span></span></p>
<p>Severe and occasionally incapacitating bone, joint, and/or <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span> has been reported with bisphosphonate use [see <span class="Italics">Warnings and Precautions (<a href="#s21">5.5</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s41"></a><a name="section-6.2.4"></a><p></p>
<p class="First"><span class="Bold Underline">Atypical Subtrochanteric and Diaphyseal Femoral <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span></span></p>
<p>Atypical subtrochanteric and diaphyseal femoral <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> have been reported with bisphosphonate therapy, including zoledronic acid injection [<span class="Italics">see Warnings and Precautions (<a href="#s22">5.6</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s42"></a><a name="section-6.2.5"></a><p></p>
<p class="First"><span class="Bold Underline">Ocular Adverse Events</span></p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span>, <span class="product-label-link" type="condition" conceptid="434944" conceptname="Scleritis">scleritis</span>, <span class="product-label-link" type="condition" conceptid="4218083" conceptname="Episcleritis">episcleritis</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>, and orbital <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> including <span class="product-label-link" type="condition" conceptid="40480516" conceptname="Orbital edema">orbital edema</span> have been reported during postmarketing use. In some cases, symptoms resolved with topical steroids.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s43"></a><a name="section-6.2.6"></a><p></p>
<p class="First"><span class="Bold Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></p>
<p>There have been rare reports of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> with intravenous zoledronic acid including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span>. Very rare cases of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>/<span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> have also been reported.
</p>
<p>Additional adverse reactions reported in postmarketing use include:
</p>
<p><span class="Bold Italics">CNS:</span> <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste disturbance</span>, <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperesthesia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>; <span class="Bold Italics">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>; <span class="Bold Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>; <span class="Bold Italics">Skin:</span> Increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>; <span class="Bold Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>; <span class="Bold Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (associated with <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> or <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span> primarily in patients with underlying risk factors); <span class="Bold Italics">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasms</span>, <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span> (ILD) with positive rechallenge; <span class="Bold Italics">Renal:</span> <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>; <span class="Bold Italics">General Disorders and Administration Site:</span> <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increase</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like illness (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> or <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>) persisting for greater than 30 days; <span class="Bold Italics">Laboratory Abnormalities:</span> <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">hypernatremia</span>.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s44"></a><a name="section-7"></a><p></p>
<h1>7  DRUG INTERACTIONS
</h1>
<p class="First"><span class="Italics">In vitro</span> studies indicate that the plasma protein binding of zoledronic acid is low, with the unbound fraction ranging from 60% to 77%. <span class="Italics">In vitro</span> studies also indicate that zoledronic acid does not inhibit microsomal CYP450 enzymes. <span class="Italics">In vivo</span> studies showed that zoledronic acid is not metabolized, and is excreted into the urine as the intact drug.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-7.1"></a><p></p>
<h2>7.1  Aminoglycosides
</h2>
<p class="First">Caution is advised when bisphosphonates are administered with aminoglycosides, since these agents may have an additive effect to lower serum calcium level for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span>. This effect has not been reported in zoledronic acid injection clinical trials.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-7.2"></a><p></p>
<h2>7.2  Loop Diuretics
</h2>
<p class="First">Caution should also be exercised when zoledronic acid injection is used in combination with loop diuretics due to an increased risk of <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-7.3"></a><p></p>
<h2>7.3  Nephrotoxic Drugs
</h2>
<p class="First">Caution is indicated when zoledronic acid injection is used with other potentially nephrotoxic drugs.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s48"></a><a name="section-7.4"></a><p></p>
<h2>7.4  Thalidomide
</h2>
<p class="First">No dose adjustment for zoledronic acid injection 4 mg is needed when coadministered with thalidomide. In a pharmacokinetic study of 24 patients with <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span>, zoledronic acid injection 4 mg given as a 15 minute infusion was administered either alone or with thalidomide (100 mg once daily on days 1 to 14 and 200 mg once daily on days 15 to 28). Coadministration of thalidomide with zoledronic acid injection did not significantly change the pharmacokinetics of zoledronic acid or creatinine clearance.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s49"></a><a name="section-8"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s50"></a><a name="section-8.1"></a><p></p>
<h2>8.1  Pregnancy
</h2>
<p class="First"><span class="Bold">Pregnancy Category D</span> [see <span class="Italics">Warnings and Precautions (<a href="#s25">5.9</a>)</span>]
</p>
<p>There are no adequate and well-controlled studies of zoledronic acid injection in pregnant women. Zoledronic acid injection may cause fetal harm when administered to a pregnant woman. Bisphosphonates, such as zoledronic acid injection, are incorporated into the bone matrix and are gradually released over periods of weeks to years. The extent of bisphosphonate incorporation into adult bone, and hence, the amount available for release back into the systemic circulation, is directly related to the total dose and duration of bisphosphonate use. Although there are no data on fetal risk in humans, bisphosphonates do cause fetal harm in animals, and animal data suggest that uptake of bisphosphonates into fetal bone is greater than into maternal bone. Therefore, there is a theoretical risk of fetal harm (e.g., skeletal and other abnormalities) if a woman becomes pregnant after completing a course of bisphosphonate therapy. The impact of variables such as time between cessation of bisphosphonate therapy to conception, the particular bisphosphonate used, and the route of administration (intravenous versus oral) on this risk has not been established. If this drug is used during pregnancy or if the patient becomes pregnant while taking or after taking this drug, the patient should be apprised of the potential hazard to the fetus.
</p>
<p>In female rats given subcutaneous doses of zoledronic acid of 0.01, 0.03, or 0.1 mg/kg/day beginning 15 days before mating and continuing through gestation, the number of <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span> was increased and survival of neonates was decreased in the mid- and high-dose groups (≥0.2 times the human systemic exposure following an intravenous dose of 4 mg, based on an AUC comparison). Adverse maternal effects were observed in all dose groups (with a systemic exposure of ≥0.07 times the human systemic exposure following an intravenous dose of 4 mg, based on an AUC comparison) and included dystocia and periparturient mortality in pregnant rats allowed to deliver. Maternal mortality may have been related to drug-induced inhibition of skeletal calcium mobilization, resulting in periparturient <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>. This appears to be a bisphosphonate-class effect.
</p>
<p>In pregnant rats given a subcutaneous dose of zoledronic acid of 0.1, 0.2, or 0.4 mg/kg/day during gestation, adverse fetal effects were observed in the mid- and high-dose groups (with systemic exposures of 2.4 and 4.8 times, respectively, the human systemic exposure following an intravenous dose of 4 mg, based on an AUC comparison). These adverse effects included increases in pre- and postimplantation losses, decreases in viable fetuses, and fetal skeletal, visceral, and external malformations. Fetal skeletal effects observed in the high-dose group included unossified or incompletely ossified bones, thickened, curved or shortened bones, wavy ribs, and shortened jaw. Other adverse fetal effects observed in the high-dose group included reduced lens, rudimentary cerebellum, reduction or absence of liver lobes, reduction of lung lobes, vessel dilation, <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. Skeletal variations were also observed in the low-dose group (with systemic exposure of 1.2 times the human systemic exposure following an intravenous dose of 4 mg, based on an AUC comparison). Signs of maternal toxicity were observed in the high-dose group and included reduced body weights and food consumption, indicating that maximal exposure levels were achieved in this study.
</p>
<p>In pregnant rabbits given subcutaneous doses of zoledronic acid of 0.01, 0.03, or 0.1 mg/kg/day during gestation (≤0.5 times the human intravenous dose of 4 mg, based on a comparison of relative body surface areas), no adverse fetal effects were observed. Maternal mortality and abortion occurred in all treatment groups (at doses ≥0.05 times the human intravenous dose of 4 mg, based on a comparison of relative body surface areas). Adverse maternal effects were associated with, and may have been caused by, drug-induced <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s51"></a><a name="section-8.2"></a><p></p>
<h2>8.3  Nursing Mothers
</h2>
<p class="First">It is not known whether zoledronic acid is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from zoledronic acid injection, a decision should be made to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Zoledronic acid binds to bone long term and may be released over weeks to years.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s52"></a><a name="section-8.3"></a><p></p>
<h2>8.4  Pediatric Use
</h2>
<p class="First">Zoledronic Acid Injection is not indicated for use in children.
</p>
<p>The safety and effectiveness of zoledronic acid was studied in a one-year active-controlled trial of 152 pediatric subjects (74 receiving zoledronic acid). The enrolled population was subjects with severe <span class="product-label-link" type="condition" conceptid="78257" conceptname="Osteogenesis imperfecta">osteogenesis imperfecta</span>, aged 1 to 17 years, 55% male, 84% Caucasian, with a mean lumbar spine bone mineral density (BMD) of 0.431 gm/cm<span class="Sup">2</span>, which is 2.7 standard deviations below the mean for age-matched controls (BMD Z-score of -2.7). At one year, increases in BMD were observed in the zoledronic acid treatment group. However, changes in BMD in individual patients with severe <span class="product-label-link" type="condition" conceptid="78257" conceptname="Osteogenesis imperfecta">osteogenesis imperfecta</span> did not necessarily correlate with the risk for <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> or the incidence or severity of chronic <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>. The adverse events observed with zoledronic acid injection use in children did not raise any new safety findings beyond those previously seen in adults treated for <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span> or bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>. However, adverse reactions seen more commonly in pediatric patients included <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (61%), <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> (26%), <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> (22%) and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (22%). These reactions, excluding <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, occurred most frequently within 3 days after the first infusion and became less common with repeat dosing. Because of long-term retention in bone, zoledronic acid injection should only be used in children if the potential benefit outweighs the potential risk.
</p>
<p>Plasma zoledronic acid concentration data was obtained from 10 patients with severe osteogenesis imperfect (4 in the age group of 3 to 8 years and 6 in the age group of 9 to 17 years) infused with 0.05 mg/kg dose over 30 min. Mean C<span class="Sub">max</span> and AUC<span class="Sub">(0-last)</span> was 167 ng/mL and 220 ng•h/mL, respectively. The plasma concentration time profile of zoledronic acid in pediatric patients represent a multi-exponential decline, as observed in adult cancer patients at an approximately equivalent mg/kg dose.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s53"></a><a name="section-8.4"></a><p></p>
<h2>8.5  Geriatric Use
</h2>
<p class="First">Clinical studies of zoledronic acid injection in <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span> included 34 patients who were 65 years of age or older. No significant differences in response rate or adverse reactions were seen in geriatric patients receiving zoledronic acid injection as compared to younger patients. Controlled clinical studies of zoledronic acid injection in the treatment of <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> and bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> of <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span> in patients over age 65 revealed similar efficacy and safety in older and younger patients. Because decreased renal function occurs more commonly in the elderly, special care should be taken to monitor renal function.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s54"></a><a name="section-9"></a><p></p>
<h1>10  OVERDOSAGE
</h1>
<p class="First">Clinical experience with acute overdosage of zoledronic acid injection is limited. Two patients received zoledronic acid injection 32 mg over 5 minutes in clinical trials. Neither patient experienced any clinical or laboratory toxicity. Overdosage may cause clinically significant <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>, and <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>. Clinically relevant reductions in serum levels of calcium, phosphorus, and magnesium should be corrected by intravenous administration of calcium gluconate, potassium or sodium phosphate, and magnesium sulfate, respectively.
</p>
<p>In an open-label study of zoledronic acid 4 mg in breast cancer patients, a female patient received a single 48-mg dose of zoledronic acid in error. Two days after the <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, the patient experienced a single episode of <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span> (38°C), which resolved after treatment. All other evaluations were normal, and the patient was discharged seven days after the <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.
</p>
<p>A patient with non-Hodgkin's <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> received zoledronic acid 4 mg daily on four successive days for a total dose of 16 mg. The patient developed <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> and <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span> with increased GGT (nearly 100 U/L, each value unknown). The outcome of this case is not known.
</p>
<p>In controlled clinical trials, administration of Zoledronic Acid Injection 4 mg as an intravenous infusion over 5 minutes has been shown to increase the risk of renal toxicity compared to the same dose administered as a 15-minute intravenous infusion. In controlled clinical trials, Zoledronic Acid Injection 8 mg has been shown to be associated with an increased risk of renal toxicity compared to Zoledronic Acid Injection 4 mg, even when given as a 15-minute intravenous infusion, and was not associated with added benefit in patients with <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span> [see <span class="Italics">Dosage and Administration (<a href="#s12">2.4</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s55"></a><a name="section-10"></a><p></p>
<h1>11  DESCRIPTION
</h1>
<p class="First">Zoledronic Acid Injection contains zoledronic acid, a bisphosphonic acid which is an inhibitor of osteoclastic bone resorption. Zoledronic acid is designated chemically as (1-Hydroxy-2-imidazol-1-yl-phosphonoethyl) phosphonic acid monohydrate and its structural formula is:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2191fccc-9f90-486c-8f30-dc828b62fe15&amp;name=zol0h-0000-01.jpg">
</div>
<p>Zoledronic acid is a white crystalline powder. Its molecular formula is
</p>
<p>C<span class="Sub">5</span>H<span class="Sub">10</span>N<span class="Sub">2</span>O<span class="Sub">7</span>P<span class="Sub">2</span>•3H<span class="Sub">2</span>O and its molar <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> is 326.14 g/Mol. Zoledronic acid is highly soluble in 0.1N sodium hydroxide solution, sparingly soluble in water and 0.1N hydrochloric acid, and practically insoluble in organic solvents. The pH of a 0.7% solution of zoledronic acid in water is approximately 2.0.
</p>
<p>Zoledronic Acid Injection, 4 mg/5 mL concentrate for intravenous infusion is available in 5-mL vials as a sterile liquid concentrate for intravenous infusion. Each 5-mL vial contains 4.794 mg of zoledronic acid trihydrate, corresponding to
</p>
<p>4 mg zoledronic acid on an anhydrous basis; 220 mg of mannitol, USP; water for injection and 24 mg sodium citrate USP.
</p>
<p><span class="Bold Italics">Inactive Ingredients:</span> mannitol, USP, as bulking agent, water for injection and sodium citrate, USP, as buffering agent.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s56"></a><a name="section-11"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s57"></a><a name="section-11.1"></a><p></p>
<h2>12.1  Mechanism of Action
</h2>
<p class="First">The principal pharmacologic action of zoledronic acid is inhibition of bone resorption. Although the antiresorptive mechanism is not completely understood, several factors are thought to contribute to this action. <span class="Italics">In vitro</span>, zoledronic acid inhibits osteoclastic activity and induces osteoclast <span class="product-label-link" type="condition" conceptid="4048757" conceptname="Apoptosis">apoptosis</span>. Zoledronic acid also blocks the osteoclastic resorption of mineralized bone and cartilage through its binding to bone. Zoledronic acid inhibits the increased osteoclastic activity and skeletal calcium release induced by various stimulatory factors released by tumors.
</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s58"></a><a name="section-11.2"></a><p></p>
<h2>12.2  Pharmacodynamics
</h2>
<p class="First">Clinical studies in patients with <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span> (HCM) showed that single-dose infusions of zoledronic acid injection are associated with decreases in serum calcium and phosphorus and increases in urinary calcium and phosphorus excretion.
</p>
<p>Osteoclastic <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> resulting in excessive bone resorption is the underlying pathophysiologic derangement in <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span> (HCM, tumor-induced <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>) and metastatic bone disease. Excessive release of calcium into the blood as bone is resorbed results in <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span> and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span>, with progressive <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> and decreasing glomerular filtration rate. This, in turn, results in increased renal resorption of calcium, setting up a cycle of worsening systemic <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>. Reducing excessive bone resorption and maintaining adequate fluid administration are, therefore, essential to the management of <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span>.
</p>
<p>Patients who have <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span> can generally be divided into two groups according to the pathophysiologic mechanism involved: humoral <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> and <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> due to tumor invasion of bone. In humoral <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, osteoclasts are activated and bone resorption is stimulated by factors such as parathyroid hormone-related protein, which are elaborated by the tumor and circulate systemically. Humoral <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> usually occurs in squamous cell malignancies of the lung or head and neck or in genitourinary tumors such as renal cell carcinoma or ovarian cancer. Skeletal <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> may be absent or minimal in these patients.
</p>
<p>Extensive invasion of bone by tumor cells can also result in <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> due to local tumor products that stimulate bone resorption by osteoclasts. Tumors commonly associated with locally mediated <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> include breast cancer and <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span>.
</p>
<p>Total serum calcium levels in patients who have <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span> may not reflect the severity of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, since concomitant <span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">hypoalbuminemia</span> is commonly present. Ideally, <span class="product-label-link" type="condition" conceptid="4125860" conceptname="Calcium electrolyte">ionized calcium</span> levels should be used to diagnose and follow hypercalcemic conditions; however, these are not commonly or rapidly available in many clinical situations. Therefore, adjustment of the total serum calcium value for differences in albumin levels (corrected serum calcium, CSC) is often used in place of measurement of <span class="product-label-link" type="condition" conceptid="4125860" conceptname="Calcium electrolyte">ionized calcium</span>; several nomograms are in use for this type of calculation [see <span class="Italics">Dosage and Administration (<a href="#s8">2.1</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s59"></a><a name="section-11.3"></a><p></p>
<h2>12.3  Pharmacokinetics
</h2>
<p class="First">Pharmacokinetic data in patients with <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> are not available.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s60"></a><a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Bold Underline">Distribution</span></p>
<p>Single or multiple (q 28 days) 5-minute or 15-minute infusions of 2, 4, 8 or 16 mg zoledronic acid injection were given to 64 patients with cancer and bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>. The postinfusion decline of zoledronic acid concentrations in plasma was consistent with a triphasic process showing a rapid decrease from peak concentrations at end of infusion to less than 1% of C<span class="Sub">max</span> 24 hours postinfusion with population half-lives of t<span class="Sub">½</span><span class="Sub">α</span> 0.24 hours and t<span class="Sub">½</span><span class="Sub">β</span> 1.87 hours for the early disposition phases of the drug. The terminal elimination phase of zoledronic acid was prolonged, with very low concentrations in plasma between Days 2 and 28 postinfusion, and a terminal elimination half-life t<span class="Sub">½</span><span class="Sub">γ</span> of 146 hours. The area under the plasma concentration versus time curve (AUC<span class="Sub">0-24h</span>) of zoledronic acid was dose proportional from 2 to 16 mg. The accumulation of zoledronic acid measured over three cycles was low, with mean AUC<span class="Sub">0-24h</span> ratios for cycles 2 and 3 versus 1 of 1.13 ± 0.30 and 1.16 ± 0.36, respectively.
</p>
<p><span class="Italics">In vitro</span> and <span class="Italics">ex vivo</span> studies showed low affinity of zoledronic acid for the cellular components of human blood, with a mean blood to plasma concentration ratio of 0.59 in a concentration range of 30 ng/mL to 5000 ng/mL. <span class="Italics">In vitro</span>, the plasma protein binding is low, with the unbound fraction ranging from 60% at 2 ng/mL to 77% at 2000 ng/mL of zoledronic acid.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s61"></a><a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Bold Underline">Metabolism</span></p>
<p>Zoledronic acid does not inhibit human P450 enzymes <span class="Italics">in vitro</span>. Zoledronic acid does not undergo biotransformation <span class="Italics">in vivo</span>. In animal studies, less than 3% of the administered intravenous dose was found in the feces, with the balance either recovered in the urine or taken up by bone, indicating that the drug is eliminated intact via the kidney. Following an intravenous dose of 20 nCi <span class="Sup">14</span>C-zoledronic acid in a patient with cancer and bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>, only a single radioactive species with chromatographic properties identical to those of parent drug was recovered in urine, which suggests that zoledronic acid is not metabolized.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s62"></a><a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Bold Underline">Excretion</span></p>
<p>In 64 patients with cancer and bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>, on average (± S.D.) 39 ± 16% of the administered zoledronic acid dose was recovered in the urine within 24 hours, with only trace amounts of drug found in urine post-Day 2. The cumulative percent of drug excreted in the urine over 0 to 24 hours was independent of dose. The balance of drug not recovered in urine over 0 to 24 hours, representing drug presumably bound to bone, is slowly released back into the systemic circulation, giving rise to the observed prolonged low plasma concentrations. The 0 to 24 hour renal clearance of zoledronic acid was 3.7 ± 2.0 L/h.
</p>
<p>Zoledronic acid clearance was independent of dose but dependent upon the patient's creatinine clearance. In a study in patients with cancer and bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>, increasing the infusion time of a 4-mg dose of zoledronic acid from 5 minutes (n=5) to 15 minutes (n=7) resulted in a 34% decrease in the zoledronic acid concentration at the end of the infusion ([mean ± SD] 403 ± 118 ng/mL versus 264 ± 86 ng/mL) and a 10% increase in the total AUC (378 ± 116 ng x h/ mL versus 420 ± 218 ng x h/mL). The difference between the AUC means was not statistically significant.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s63"></a><a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Bold Underline">Special Populations</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s64"></a><a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Bold Italics">Pediatrics</span></p>
<p>Zoledronic Acid Injection is not indicated for use in children [see <span class="Italics">Use in Specific Populations (<a href="#s52">8.4</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s65"></a><a name="section-11.3.6"></a><p></p>
<p class="First"><span class="Bold Italics">Geriatrics</span></p>
<p>The pharmacokinetics of zoledronic acid were not affected by age in patients with cancer and bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> who ranged in age from 38 years to 84 years.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s66"></a><a name="section-11.3.7"></a><p></p>
<p class="First"><span class="Bold Italics">Race</span></p>
<p>Population pharmacokinetic analyses did not indicate any differences in pharmacokinetics among Japanese and North American (Caucasian and African American) patients with cancer and bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s67"></a><a name="section-11.3.8"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></span></p>
<p>No clinical studies were conducted to evaluate the effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of zoledronic acid.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s68"></a><a name="section-11.3.9"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></span></p>
<p>The pharmacokinetic studies conducted in 64 cancer patients represented typical clinical populations with normal to moderately <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Compared to patients with normal renal function (N=37), patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (N=15) showed an average increase in plasma AUC of 15%, whereas patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (N=11) showed an average increase in plasma AUC of 43%. Limited pharmacokinetic data are available for zoledronic acid injection in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance less than 30 mL/ min). Based on population PK/PD modeling, the risk of renal deterioration appears to increase with AUC, which is doubled at a creatinine clearance of 10 mL/min. Creatinine clearance is calculated by the Cockcroft-Gault formula:
</p>
<dl>
<dt> 
</dt>
<dd>CrCl =  <span class="Underline">[140-age (years)] x weight (kg)
</span><span class="Underline">{</span><span class="Underline">x 0.85 for female patients}</span><br>              [72 x serum creatinine (mg/dL)]
</dd>
</dl>
<p>Zoledronic Acid Injection systemic clearance in individual patients can be calculated from the population clearance of zoledronic acid injection, CL (L/h)=6.5(CrCl/90)<span class="Sup">0.4</span>. These formulae can be used to predict the zoledronic acid injection AUC in patients, where CL = Dose/AUC<span class="Sub">0-</span><span class="Sub">∞</span>. The average AUC<span class="Sub">0-24</span> in patients with normal renal function was 0.42 mg·h/L and the calculated AUC<span class="Sub">0-</span><span class="Sub">∞</span> for a patient with creatinine clearance of 75 mL/min was 0.66 mg·h/L following a 4-mg dose of zoledronic acid injection. However, efficacy and safety of adjusted dosing based on these formulae have not been prospectively assessed [<span class="Italics">see Warnings and Precautions (<a href="#s19">5.3</a>)</span>].
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s69"></a><a name="section-12"></a><p></p>
<h1>13  NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s70"></a><a name="section-12.1"></a><p></p>
<h2>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Standard lifetime carcinogenicity bioassays were conducted in mice and rats. Mice were given oral doses of zoledronic acid of 0.1, 0.5, or 2.0 mg/kg/day. There was an increased incidence of Harderian gland <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in males and females in all treatment groups (at doses ≥0.002 times a human intravenous dose of 4 mg, based on a comparison of relative body surface areas). Rats were given oral doses of zoledronic acid of 0.1, 0.5, or 2.0 mg/kg/day. No increased incidence of tumors was observed (at doses ≤0.2 times the human intravenous dose of 4 mg, based on a comparison of relative body surface areas).
</p>
<p>Zoledronic acid was not genotoxic in the Ames bacterial mutagenicity assay, in the Chinese hamster ovary cell assay, or in the Chinese hamster gene mutation assay, with or without metabolic activation. Zoledronic acid was not genotoxic in the <span class="Italics">in vivo</span> rat micronucleus assay.
</p>
<p>Female rats were given subcutaneous doses of zoledronic acid of 0.01, 0.03, or 0.1 mg/kg/day beginning 15 days before mating and continuing through gestation. Effects observed in the high-dose group (with systemic exposure of 1.2 times the human systemic exposure following an intravenous dose of 4 mg, based on AUC comparison) included inhibition of ovulation and a decrease in the number of pregnant rats. Effects observed in both the mid-dose group (with systemic exposure of 0.2 times the human systemic exposure following an intravenous dose of 4 mg, based on an AUC comparison) and high-dose group included an increase in preimplantation losses and a decrease in the number of implantations and live fetuses.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s71"></a><a name="section-13"></a><p></p>
<h1>14  CLINICAL STUDIES
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s72"></a><a name="section-13.1"></a><p></p>
<h2>14.1  <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">Hypercalcemia of Malignancy</span>
</h2>
<p class="First">Two identical multicenter, randomized, double-blind, double-dummy studies of zoledronic acid injection 4 mg given as a 5-minute intravenous infusion or pamidronate 90 mg given as a 2-hour intravenous infusion were conducted in 185 patients with <span class="product-label-link" type="condition" conceptid="4166232" conceptname="Humoral hypercalcemia of malignancy">hypercalcemia of malignancy</span> (HCM). NOTE: Administration of zoledronic acid injection 4 mg given as a 5-minute intravenous infusion has been shown to result in an increased risk of renal toxicity, as measured by increases in serum creatinine, which can progress to <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. The incidence of renal toxicity and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> has been shown to be reduced when zoledronic acid injection 4 mg is given as a 15-minute intravenous infusion. Zoledronic Acid Injection should be administered by intravenous infusion over no less than 15 minutes [<span class="Italics">see Warnings and Precautions (5.1 and 5.2)</span> and <span class="Italics">Dosage and Administration (<a href="#s12">2.4</a>)</span>]. The treatment groups in the clinical studies were generally well balanced with regards to age, sex, race, and tumor types. The mean age of the study population was 59 years; 81% were Caucasian, 15% were Black, and 4% were of other races. 60% of the patients were male. The most common tumor types were lung, breast, head and neck, and renal.
</p>
<p>In these studies, HCM was defined as a corrected serum calcium (CSC) concentration of greater than or equal to 12.0 mg/dL (3.00 mmol/L). The primary efficacy variable was the proportion of patients having a complete response, defined as the lowering of the CSC to less than or equal to 10.8 mg/dL (2.70 mmol/L) within 10 days after drug infusion.
</p>
<p>To assess the effects of zoledronic acid injection versus those of pamidronate, the two multicenter HCM studies were combined in a preplanned analysis. The results of the primary analysis revealed that the proportion of patients that had normalization of corrected serum calcium by Day 10 were 88% and 70% for zoledronic acid injection 4 mg and pamidronate 90 mg, respectively (P=0.002) (see Figure 1). In these studies, no additional benefit was seen for zoledronic acid injection 8 mg over zoledronic acid injection 4 mg; however, the risk of renal toxicity of zoledronic acid injection 8 mg was significantly greater than that seen with zoledronic acid injection 4 mg.
</p>
<p><span class="Bold">Figure 1</span></p>
<div class="Figure">
<a name="f02"></a><img alt="Figure 1
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2191fccc-9f90-486c-8f30-dc828b62fe15&amp;name=zol0h-0000-02.jpg">
</div>
<p>Secondary efficacy variables from the pooled HCM studies included the proportion of patients who had normalization of corrected serum calcium (CSC) by Day 4; the proportion of patients who had normalization of CSC by Day 7; time to relapse of HCM; and duration of complete response. Time to relapse of HCM was defined as the duration (in days) of normalization of serum calcium from study drug infusion until the last CSC value less than 11.6 mg/dL (less than 2.90 mmol/L). Patients who did not have a complete response were assigned a time to relapse of 0 days. Duration of complete response was defined as the duration (in days) from the occurrence of a complete response until the last CSC ≤10.8 mg/dL (2.70 mmol/L). The results of these secondary analyses for zoledronic acid injection 4 mg and pamidronate 90 mg are shown in <a href="#t10">Table 10</a>.
</p>
<a name="t10"></a><table width="100%">
<caption><span>Table 10: Secondary Efficacy Variables in Pooled HCM Studies
</span></caption>
<col align="left" width="28.980%">
<col align="left" width="8.200%">
<col align="left" width="27.120%">
<col align="left" width="8.580%">
<col align="left" width="27.120%">
<tfoot><tr class="First Last"><td class="Botrule Lrule Rrule" align="left" colspan="5" valign="top"><p class="First Footnote">* P less than 0.05 versus pamidronate 90 mg.
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Zoledronic Acid Injection 4 mg</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Pamidronate 90 mg</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">Complete Response</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">N</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Response Rate</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">N</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Response Rate</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">By Day 4</span><br><span class="Bold">By Day 7</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">86<br>86
</td>
<td class="Botrule Rrule" align="center" valign="top">45.3%<br>82.6%*
</td>
<td class="Botrule Rrule" align="center" valign="top">99<br>99
</td>
<td class="Botrule Rrule" align="center" valign="top">33.3%<br>63.6%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><span class="Bold">Duration of Response</span></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">N</span></td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">Median</span><br><span class="Bold">Duration</span><br><span class="Bold">(Days)</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">N</span></td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">Median</span><br><span class="Bold">Duration</span><br><span class="Bold">(Days)</span>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">Time of Relapse</span><br><span class="Bold">Duration of Complete Response</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">86<br>76
</td>
<td class="Botrule Rrule" align="center" valign="top">30*<br>32
</td>
<td class="Botrule Rrule" align="center" valign="top">99<br>69
</td>
<td class="Botrule Rrule" align="center" valign="top">17<br>18
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s73"></a><a name="section-13.2"></a><p></p>
<h2>14.2   Clinical Trials in <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple Myeloma</span> and Bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">Metastases</span> of <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">Solid Tumors</span>
</h2>
<p class="First"><a href="#t11">Table 11</a> describes an overview of the efficacy population in three randomized zoledronic acid injection trials in patients with <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> and bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> of <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>. These trials included a pamidronate-controlled study in breast cancer and <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span>, a placebo-controlled study in prostate cancer, and a placebo-controlled study in other <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>. The prostate cancer study required documentation of previous bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> and 3 consecutive rising PSAs while on hormonal therapy. The other placebo-controlled <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumor</span> study included patients with bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span> from malignancies other than breast cancer and prostate cancer, including NSCLC, renal cell cancer, small cell lung cancer, colorectal cancer, <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>, GI/genitourinary cancer, head and neck cancer, and others. These trials were comprised of a core phase and an extension phase. In the <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumor</span>, breast cancer and <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> trials, only the core phase was evaluated for efficacy as a high percentage of patients did not choose to participate in the extension phase. In the prostate cancer trials, both the core and extension phases were evaluated for efficacy showing the zoledronic acid injection effect during the first 15 months was maintained without decrement or improvement for another 9 months. The design of these clinical trials does not permit assessment of whether more than one-year administration of zoledronic acid injection is beneficial. The optimal duration of zoledronic acid injection administration is not known.
</p>
<p>The studies were amended twice because of renal toxicity. The zoledronic acid injection infusion duration was increased from 5 minutes to 15 minutes. After all patients had been accrued, but while dosing and follow-up continued, patients in the 8 mg zoledronic acid injection treatment arm were switched to 4 mg due to toxicity. Patients who were randomized to the zoledronic acid injection 8 mg group are not included in these analyses.
</p>
<a name="t11"></a><table width="100%">
<caption><span>Table 11: Overview of Efficacy Population for Phase III Studies
</span></caption>
<col align="left" width="29.426%">
<col align="left" width="12.823%">
<col align="left" width="18.284%">
<col align="left" width="19.604%">
<col align="left" width="19.864%">
<tfoot><tr class="First Last"><td class="Botrule Lrule Rrule" align="left" colspan="5" valign="top"><p class="First Footnote">* Patients who were randomized to the 8 mg Zoledronic Acid Injection group are not included in any of the analyses in this package insert.
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="middle"><span class="Bold">Patient Population</span></td>
<td class="Botrule Rrule Toprule" align="left" valign="middle"><span class="Bold">No. of Patients</span></td>
<td class="Botrule Rrule Toprule" align="left" valign="middle">
<span class="Bold">Zoledronic</span><br><span class="Bold">Acid</span><br><span class="Bold">Injection</span><br><span class="Bold">Dose</span>
</td>
<td class="Botrule Rrule Toprule" align="left" valign="middle"><span class="Bold">Control</span></td>
<td class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Median</span><br><span class="Bold">Duration</span><br><span class="Bold">(Planned</span><br><span class="Bold">Duration)</span><br><span class="Bold">Zoledronic</span><br><span class="Bold">Acid Injection</span><br><span class="Bold">4 mg</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple myeloma</span> or metastatic breast cancer
</td>
<td class="Botrule Rrule" align="left" valign="top">1,648
</td>
<td class="Botrule Rrule" align="left" valign="top">4 and 8* mg<br>Q3-4 weeks
</td>
<td class="Botrule Rrule" align="left" valign="top">Pamidronate<br>90 mg<br>Q3-4 weeks
</td>
<td class="Botrule Rrule" align="left" valign="top">12.0 months<br>(13 months)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Metastatic prostate cancer
</td>
<td class="Botrule Rrule" align="left" valign="top">643
</td>
<td class="Botrule Rrule" align="left" valign="top">4 and 8* mg<br>Q3 weeks
</td>
<td class="Botrule Rrule" align="left" valign="top">Placebo
</td>
<td class="Botrule Rrule" align="left" valign="top">10.5 months<br>(15 months)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Metastatic <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumor</span> other than breast or prostate cancer
</td>
<td class="Botrule Rrule" align="left" valign="top">773
</td>
<td class="Botrule Rrule" align="left" valign="top">4 and 8* mg<br>Q3 weeks
</td>
<td class="Botrule Rrule" align="left" valign="top">Placebo
</td>
<td class="Botrule Rrule" align="left" valign="top">3.8 months<br>(9 months)
</td>
</tr>
</tbody>
</table>
<p>Each study evaluated skeletal-related events (SREs), defined as any of the following: pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>, radiation therapy to bone, surgery to bone, or <span class="product-label-link" type="condition" conceptid="4322945" conceptname="Spinal cord compression">spinal cord compression</span>. Change in antineoplastic therapy due to increased <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> was a SRE in the prostate cancer study only. Planned analyses included the proportion of patients with a SRE during the study and time to the first SRE. Results for the two zoledronic acid injection placebo-controlled studies are given in <a href="#t12">Table 12</a>.
</p>
<a name="t12"></a><table width="100%">
<caption><span>Table 12: Zoledronic Acid Injection Compared to Placebo in Patients with Bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">Metastases</span> from Prostate Cancer or Other <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">Solid Tumors</span>
</span></caption>
<col align="left" width="8.788%">
<col align="left" width="10.143%">
<col align="left" width="11.054%">
<col align="left" width="11.110%">
<col align="left" width="3.544%">
<col align="left" width="13.410%">
<col align="left" width="13.343%">
<col align="left" width="13.843%">
<col align="left" width="14.765%">
<tfoot>
<tr class="First"><td align="left" colspan="9" valign="top"><p class="First Footnote"><span class="Sup">1</span>SRE=Skeletal-Related Event
</p></td></tr>
<tr><td align="left" colspan="9" valign="top"><p class="First Footnote"><span class="Sup">2</span>Difference for the proportion of patients with a SRE of Zoledronic Acid Injection 4 mg versus placebo.
</p></td></tr>
<tr class="Last"><td align="left" colspan="9" valign="top"><p class="First Footnote"><span class="Sup">3</span>Hazard ratio for the first occurrence of a SRE of Zoledronic Acid Injection 4 mg versus placebo.
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="left" valign="top"></td>
<td class="Botrule Toprule" align="left" colspan="3" valign="top">
<span class="Bold">I. Analysis of Proportion of Patients  with a SRE</span><span class="Bold"><span class="Sup">1</span></span>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="top"><span class="Bold">II. Analysis of Time to the First SRE</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><span class="Bold">Study</span></td>
<td class="Botrule Rrule" align="center" valign="bottom">
<span class="Bold">Study Arm &amp; Patient</span><br><span class="Bold">Number</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">Proportion</span></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="bottom">
<span class="Bold">Difference</span><span class="Bold"><span class="Sup">2</span></span><span class="Bold">&amp; 95% Cl</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">P-value</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">Median (Days)</span></td>
<td class="Botrule Rrule" align="center" valign="bottom">
<span class="Bold">Hazard</span><br><span class="Bold">Ratio</span><span class="Bold"><span class="Sup">3
</span></span><span class="Bold">&amp;</span><br><span class="Bold">95% Cl</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">P-value</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">
<span class="Bold">Prostate</span><br><span class="Bold">Cancer</span><br><br><br><br>
</td>
<td class="Rrule" align="center" valign="top">Zoledronic<br>Acid<br>Injection<br>4 mg<br>(n=214)<br>
</td>
<td class="Rrule" align="center" valign="top">33%<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">-11%<br>(-20%, -1%)<br>
</td>
<td class="Rrule" align="center" valign="top">0.02<br>
</td>
<td class="Rrule" align="center" valign="top">Not<br>Reached<br>
</td>
<td class="Rrule" align="center" valign="top">0.67<br>(0.49,<br>0.91)<br>
</td>
<td class="Rrule" align="center" valign="top">0.011<br>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="center" valign="top">Placebo<br>(n=208)<br>
</td>
<td class="Rrule" align="center" valign="top">44%<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top">321<br>
</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">
<span class="Bold">Solid</span><br><span class="Bold">Tumors</span>
</td>
<td class="Rrule" align="center" valign="top">Zoledronic<br>Acid<br>Injection<br>4 mg<br>(n=257)<br>
</td>
<td class="Rrule" align="center" valign="top">38%<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">-7%<br>(-15%, 2%)
</td>
<td class="Rrule" align="center" valign="top">0.13
</td>
<td class="Rrule" align="center" valign="top">230<br>
</td>
<td class="Rrule" align="center" valign="top">0.73<br>(0.55,<br>0.96)
</td>
<td class="Rrule" align="center" valign="top">0.023
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">Placebo<br>(n=250)
</td>
<td class="Botrule Rrule" align="center" valign="top">44%
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">163
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
</tbody>
</table>
<p>In the breast cancer and <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">myeloma</span> trial, efficacy was determined by a noninferiority analysis comparing Zoledronic Acid Injection to pamidronate 90 mg for the proportion of patients with a SRE. This analysis required an estimation of pamidronate efficacy. Historical data from 1,128 patients in three pamidronate placebo-controlled trials demonstrated that pamidronate decreased the proportion of patients with a SRE by 13.1% (95% Cl = 7.3%, 18.9%). Results of the comparison of treatment with Zoledronic Acid Injection compared to pamidronate are given in <a href="#t13">Table 13</a>.
</p>
<a name="t13"></a><table width="100%">
<caption><span>Table 13: Zoledronic Acid Injection Compared to Pamidronate in Patients with <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple Myeloma</span> or Bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">Metastases</span> from Breast Cancer
</span></caption>
<col align="left" width="12.500%">
<col align="left" width="12.500%">
<col align="left" width="12.500%">
<col align="left" width="12.500%">
<col align="left" width="12.500%">
<col align="left" width="12.500%">
<col align="left" width="12.500%">
<col align="left" width="12.500%">
<tfoot>
<tr class="First"><td align="left" colspan="8" valign="top"><p class="First Footnote"><span class="Sup">1</span>SRE=Skeletal-Related Event
</p></td></tr>
<tr><td align="left" colspan="8" valign="top"><p class="First Footnote"><span class="Sup">2</span>Difference for the proportion of patients with a SRE of Zoledronic Acid Injection    4 mg versus pamidronate 90 mg.
</p></td></tr>
<tr class="Last"><td align="left" colspan="8" valign="top"><p class="First Footnote"><span class="Sup">3</span>Hazard ratio for the first occurrence of a SRE of Zoledronic Acid Injection 4 mg  versus pamidronate 90 mg.
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="left" valign="top"></td>
<td class="Botrule Toprule" align="left" colspan="3" valign="top">
<span class="Bold">I. Analysis of Proportion of Patients  with a SRE</span><span class="Bold"><span class="Sup">1</span></span><br>
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="left" colspan="3" valign="top"><span class="Bold">II. Analysis of Time to the First SRE</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">Study</span></td>
<td class="Botrule Rrule" align="center" valign="bottom">
<span class="Bold">Study Arm &amp; Patient</span><br><span class="Bold">Number</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">Proportion</span></td>
<td class="Botrule Rrule" align="center" valign="bottom">
<span class="Bold">Difference</span><span class="Bold"><span class="Sup">2
</span></span><span class="Bold">&amp; 95% Cl</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">P-value</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">Median (Days)</span></td>
<td class="Botrule Rrule" align="center" valign="bottom">
<span class="Bold">Hazard</span><br><span class="Bold">Ratio</span><span class="Bold"><span class="Sup">3
</span></span><span class="Bold">&amp;</span><br><span class="Bold">95% Cl</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">P-value</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">Multiple</span><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Myeloma</span> &amp; Breast</span><br><span class="Bold">Cancer</span>
</td>
<td class="Rrule" align="center" valign="top">Zoledronic<br>Acid<br>Injection<br>4 mg<br>(n=561)<br>
</td>
<td class="Rrule" align="center" valign="top">44%<br>
</td>
<td class="Rrule" align="center" valign="top">-2%<br>(-7.9%,<br>3.7%)
</td>
<td class="Rrule" align="center" valign="top">0.46
</td>
<td class="Rrule" align="center" valign="top">373<br>
</td>
<td class="Rrule" align="center" valign="top">0.92<br>(0.77,<br>1.09)
</td>
<td class="Rrule" align="center" valign="top">0.32
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">Pamidronate<br>(n=555)
</td>
<td class="Botrule Rrule" align="center" valign="top">46%
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">363
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s74"></a><a name="section-14"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First">Zoledronic Acid Injection 4 mg/5 mL is available in
</p>
<p>NDC 17478-327-05             Carton of 1 vial<br>NDC 17478-327-45             Carton of 4 vials
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s75"></a><a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">Storage:</span></p>
<p>Store at 25°C (77°F); excursions permitted to 15º to 30°C (59º to 86°F) [see USP Controlled Room Temperature].
</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s76"></a><a name="section-15"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION
</h1>
<ul class="Disc">
<li>Patients should be instructed to tell their doctor if they have kidney problems before being given zoledronic acid injection.
</li>
<li>Patients should be informed of the importance of getting their blood tests (serum creatinine) during the course of their zoledronic acid injection therapy.
</li>
<li>Zoledronic Acid Injection should not be given if the patient is pregnant or plans to become pregnant, or if she is breastfeeding.
</li>
<li>Patients should be advised to have a dental examination prior to treatment with zoledronic acid injection and should avoid invasive dental procedures during treatment.
</li>
<li>Patients should be informed of the importance of good dental hygiene and routine dental care.
</li>
<li>Patients with <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> and bone <span class="product-label-link" type="condition" conceptid="4147162" conceptname="Secondary malignant neoplasm of respiratory and digestive systems">metastasis</span> of <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span> should be advised to take an oral calcium supplement of 500 mg and a multiple vitamin containing 400 IU of Vitamin D daily.
</li>
<li>Patients should be advised to report any thigh, hip or <span class="product-label-link" type="condition" conceptid="4010361" conceptname="Inguinal pain">groin pain</span>. It is unknown whether the risk of atypical <span class="product-label-link" type="condition" conceptid="442560" conceptname="Fracture of femur">femur fracture</span> continues after stopping therapy.
</li>
<li>Patients should be aware of the most common side effects including: <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, lower limb <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, decreased weight, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, malignant neoplasm aggravated, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>.
</li>
<li>There have been reports of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span> in aspirin-sensitive patients receiving bisphosphonates, including zoledronic acid. Before being given zoledronic acid, patients should tell their doctor if they are aspirin-sensitive.
</li>
</ul>
<p class="First">Reclast<span class="Sup">®</span> is the registered trademark of Novartis.
</p>
<p><span class="Bold">AKORN</span></p>
<p>Manufactured for: <span class="Bold">Akorn, Inc.
</span><br>Lake Forest, IL  60045<br>Manufactured by: <br>Fresenius Kabi, Austria GmbH Graz
</p>
<p><span class="Bold">Made in Austria</span></p>
<p>FKZA00N <br>Rev. 11/14
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s77"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel Text for Container Label:</span></p>
<p>NDC 17478-327-05
</p>
<p>Zoledronic Acid
</p>
<p>Injection
</p>
<p>4 mg/5 mL (0.8 mg/mL)
</p>
<p>CONCENTRATE FOR
</p>
<p>INTRAVENOUS INFUSION
</p>
<p>Not for direct injection.
</p>
<p>Dose must be diluted.
</p>
<p>Rx only
</p>
<p>5 mL Single Use Vial
</p>
<p>Sterile Concentrate
</p>
<div class="Figure">
<a name="f03"></a><img alt="Principal Display Panel Text for Container Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2191fccc-9f90-486c-8f30-dc828b62fe15&amp;name=zol0h-0000-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s78"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel Text for Carton Label:</span></p>
<p>NDC 17478-327-05
</p>
<p>Zoledronic Acid Injection
</p>
<p>4 mg/5 mL (0.8 mg/mL)
</p>
<p>CONCENTRATE FOR INTRAVENOUS INFUSION
</p>
<p>Not for direct injection. Dose must be diluted. Rx only
</p>
<p>See package insert for Preparation of Solution.
</p>
<p>Do not mix with calcium-containing infusion solutions. Akorn Logo
</p>
<p>One 5 mL Single Use Vial  Sterile Concentrate
</p>
<div class="Figure">
<a name="f04"></a><img alt="Principal Display Panel Text for Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2191fccc-9f90-486c-8f30-dc828b62fe15&amp;name=zol0h-0000-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZOLEDRONIC ACID 		
					</strong><br><span class="contentTableReg">zoledronic acid injection, solution, concentrate</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:17478-327</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Zoledronic Acid</strong> (Zoledronic Acid Anhydrous) </td>
<td class="formItem">Zoledronic Acid Anhydrous</td>
<td class="formItem">4 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Mannitol</strong></td>
<td class="formItem">220 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Citrate</strong></td>
<td class="formItem">24 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:17478-327-05</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:17478-327-45</td>
<td class="formItem">4  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202548</td>
<td class="formItem">05/22/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Akorn
							(062649876)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>10d35424-facc-4067-907d-2e52e5d74647</div>
<div>Set id: 2191fccc-9f90-486c-8f30-dc828b62fe15</div>
<div>Version: 2</div>
<div>Effective Time: 20140602</div>
</div>
</div> <div class="DistributorName">Akorn</div></p>
</body></html>
